[go: up one dir, main page]

WO1994029335A1 - Nouveaux derives peptidiques - Google Patents

Nouveaux derives peptidiques Download PDF

Info

Publication number
WO1994029335A1
WO1994029335A1 PCT/SE1994/000534 SE9400534W WO9429335A1 WO 1994029335 A1 WO1994029335 A1 WO 1994029335A1 SE 9400534 W SE9400534 W SE 9400534W WO 9429335 A1 WO9429335 A1 WO 9429335A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
phe
cha
carbon atoms
compound according
Prior art date
Application number
PCT/SE1994/000534
Other languages
English (en)
Inventor
Karl Thomas Antonsson
Ruth Bylund
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Priority to JP7501664A priority Critical patent/JPH08511017A/ja
Priority to EP94917871A priority patent/EP0701567A1/fr
Priority to AU69408/94A priority patent/AU685465B2/en
Publication of WO1994029335A1 publication Critical patent/WO1994029335A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • this invention relates to protease inhibition and treatment of inflammatory diseaes. More specifically this invention relates to new competitive inhibitors of trypsin-like serine proteases such as kininogenases, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds for treatment of inflammatory disorders, e.g. asthma, rhinitis, urticaria, inflammatory bowel diseaes, and arthritis.
  • trypsin-like serine proteases such as kininogenases
  • pharmaceutical compositions containing the compounds as active ingredients e.g. asthma, rhinitis, urticaria, inflammatory bowel diseaes, and arthritis.
  • Kininogenases are serine proteases .that act on kininogens to produce kinins (bradykinin, kallidin, and Met-Lys- bradykinin) . Plasma kallikrein, tissue kallikrein, and mast cell tryptase represent important kininogenases.
  • Kinins are generally involved in inflammation.
  • the active inflammation process is associated with increased permeability of the blood vessels resulting in extravasation of plasma into the tissue.
  • the ensuing plasma exudate contains all the protein systems of circulating blood.
  • the plasma-derived kininogens inevitably will be interacting with different kallikreins, forming kinins continually as long as the active plasma exudation process is ongoing.
  • Plasma exudation occurs independent of the mechanisms that are involved in the inflammation, whether it is allergy, infection or other factors (Persson et al., Editorial, Thorax, 1992, 47:993-1000).
  • Plasma exudation is thus a feature of many diseases including asthma, rhinitis, common cold, and inflammatory bowel diseases. Particulary in allergy mast cell tryptase will be released (Salomonsson et al.. Am. Rev. Respir. Dis., 1992, 146:1535-1542) to contribute to kinin formation and other pathogenic events in asthma, rhinitis, and intestinal diseases.
  • the kinins are biologically highly active substances with smooth muscle effects, sectretory effects, neurogenic effects, and actions that may perpetuate inflammatory processes including activation of phospholipase A 2 and increasing vascular permeability. The latter action potentially induces a vicious circle with kinins providing for the generation of more kinins etc.
  • Tissue kallikrein cleaves primarily low molecular weight kininogen to produce kallidin and plasma kallikrein preferably releases bradykinin from high molecular weight kininogen.
  • arginine chloro ethyl ketones were reported as plasma kallikrein inhibitors by Kettner and Shaw in Biochemistry 1978, 17:4778-4784 and Meth. Enzy . 1981, 80:826-842.
  • esters and amides were reported by Fareed et al. in Ann. N.Y. Acad. Sci. 1981, 370:765-784 to be plasma kallikrein inhibitors.
  • protease enzym inhibitors based on analogues of peptidase substrates, including kallikrein, are described.
  • Inhibitors of trypsin like serine proteases such as thrombin and kallikrein, based on C-terminal boronic acid derivatives of arginine and isothiouronium analogues thereof have been reported in EP-A2-0,293,881.
  • An objective of the present invention is to provide novel and potent kallikrein inhibitors with competitive inhibitory activity towards the enzyme i.e. causing reversible inhibition.
  • a further objective is to obtain inhibitors which can be given orally, dermally, rectally, or via the inhalation route.
  • n is an integer 2, 3, 4, 5, or 6; preferably 3 or 4;
  • a 1 represents a structural fragment of Formulae Ila, lib, He, lid or He; no ⁇ d wherein:
  • p is an integer 0,1 or 2;
  • n is an integer 1, 2, 3, or 4, preferably 2;
  • q is an integer 0,1 or 2, preferably 1;
  • R 1 represents H, an alkyl group having 1 to 4 carbon atoms, a hydroxyalkyl group having 2-3 carbon atoms or R 11 00C-alkyl-, where the alkyl group has 1 to 4 carbon atoms and R 11 is H or an alkyl group having 1 to 4 carbon atoms, or
  • R 1 represents R 12 00C-l,4-phenyl-CH 2 -, wherein R 12 is H or an alkyl group having 1 to 4 carbon atoms, or
  • R 1 represents R 13 -NH-C0-alkyl-, wherein the alkyl group has 1 to 4 carbon atoms and is possibly substituted alpha to the carbonyl with an alkyl group having 1 to 4 carbon atoms and wherein R 13 is H or an alkyl group having 1 to 4 carbon atoms or -CH 2 COOR 12 , wherein R 12 is as defined above, or R 1 represents R 14 S0 2 -, Ph(4-COOR 12 )-S0 2 -, Ph(3-COOR - 1122 )) -S0 2 -, or
  • R 1 represents CO-R 15 , wherein R 15 is an alkyl group having 1-4 carbon atoms, or
  • R 1 represents CO-OR 15 , wherein R 15 is as defined above, or
  • R 1 represent CO-(CH 2 ) p -COOR 12 , wherein R 12 and p are as defined above, or
  • R 1 represents -CH 2 PO(OR 16 ) 2 , wherein R 16 is, individually at each occurrence, H, methyl or ethyl;
  • R 2 represents H or an alkyl group having 1 to 4 carbon atoms or R 21 OOC-alkyl-, wherein the alkyl group has 1 to 4 carbon atoms and is possibly substituted in the position which is alpha to the carbonyl group, and the alpha substituent is a group R 22 -(CH 2 ) p -, wherein p is as defined above and R 22 is methyl, phenyl, OH, COOR 21 , and R 21 is H or an alkyl group having 1 to 4 carbon atoms;
  • R 3 represents an alkyl group having 1-4 carbon atoms, or
  • R 3 represents a cyclohexyl- or cyclopentyl group
  • R 3 represents a phenyl group which may or may not be substituted with an alkyl group having 1 to 4 carbon atoms, or with a group OR 21 , wherein R 21 is as defined above or
  • a ⁇ 2 2 represents a structural fragment
  • R 3 and p are as defined above;
  • alkyl group may be straight or branched unless specified otherwise.
  • Alkyl groups having 1 to 4 carbon atoms are methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl. When unsaturation is referred to, a carbon- carbon double bond is intended. Abbreviations are listed at the end of this specification.
  • compounds of the general Formula I are potent inhibitors of trypsin-like serine proteases and especially plasma and/or tissue kallikrein:
  • Compounds of Formula I having S-configuration on the A 2 amino acid are preferred ones, of those compounds also having R-configuration on the A 1 amino acid are particularly preferred ones.
  • Preferred compounds of the invention include:
  • Particularly preferred compounds are ;
  • the invention also provides compositions and methods for the treatment of physiological disorders and especially inflammatory diseases such as asthma, rhinitis, pancreatitis, uticaria, inflammatory bowel diseaes, and arthritis.
  • An effective amount of Formula I with or without a physiologically acceptable carrier or diluent can be used solely or in combination with other therapeutic agents.
  • the compositions may be administered via oral, dermal, nasal, tracheal, bronchial, parenteral, or rectal routes at varying doses.
  • the compounds inhibit the activity of kallikreins assessed with chromogenic substrates according to known procedures.
  • the anti-inflammatory actions of the present compounds can for example be studied by their inhibition of allergen- induced exudative inflammatory processes in airway mucosa or gut mucosa.
  • K L determinations were made with a chromogenic substrate method, and performed on a Cobas Bio centrifugal analyzer manufactured by Roche (Basel, Switzerland). Residual enzyme activity after incubation of human plasma kallikrein with various concentrations of test compound was determined at three different substrate concentrations, and measured as change in optical absorbance at 405 nm and 37°C.
  • Human plasma kallikrein (E.C.3.4.21.34, Chromogenix AB, M ⁇ lndal, Sweden), 250 ⁇ l of 0.4 nkat/ml in buffer (0.05 mol/1 Tris-HCl, pH 7.4, 1 0.15 adjusted with NaCl) with bovine albumin 5 g/1 (cat no 810033, ICI Biochemicals Ltd, High Wycombe, Bucks, GB) , was incubated for 300 s with 80 ⁇ l of test compound solution in 0.15 mol/1 NaCl containing albumin 10 g/1. An additional 10 ⁇ l of water was supplied in this step. Then 40 ⁇ l of kallikrein substrate (S-2302, Chromogenix AB, 1.25, 2.0 or 4.0 mmol/1 in water) was added together with another 20 ⁇ l of water, and the absorbance change monitored.
  • buffer 0.05 mol/1 Tris-HCl, pH 7.4, 1 0.15 adjusted with NaCl
  • bovine albumin 5 g/1 catalog no 810033
  • the compounds of the Formula I will normally be administered by the oral, rectal, dermal, nasal or parenteral route in the form of pharmaceutical preparations comprising the active ingredient either as a free base or a pharmaceutical acceptable non-toxic organic or inorganic acid addition salt, e.g. the hydrochloride, hydrobromide, lactate, acetate, citrate and trifluoroacetate and the like in a pharmaceutically acceptable dosage form.
  • a pharmaceutical acceptable non-toxic organic or inorganic acid addition salt e.g. the hydrochloride, hydrobromide, lactate, acetate, citrate and trifluoroacetate and the like in a pharmaceutically acceptable dosage form.
  • the dosage form may be a solid, semisolid or liquid preparation prepared by per se known techniques.
  • the active substance will constitute between 0.1 and 99 % by weight of the preparation, more specifically between 0.1 and 50 % by weight for preparations intended for parenteral administration and between 0.2 and 75 % by weight for preparations suitable for oral administration.
  • Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.001-100 mg/kg body weight at peroral administration and 0.001-50 g/kg body weight at parenteral administration.
  • a further objective of the invention is the mode of preparation of the compounds.
  • the compounds of Formula I may be prepared by coupling of an N-terminally protected dipeptide (W 1 -A 1 -A 2 -OH) or amino acid (W 1 -A 2 -OH) , when a N- terminally protected amino acid is used a second amino acid is added afterwards using standard methods, to a compound
  • a 1 , A 2 and n are as defined with Formula I and X is an unprotected or protected guanidino group or a protected amino group, or a group transferable into an amino group, where the amino group is subsequently transferred into an unprotected or protected guanidino group, followed by removal of the protecting group(s) or deprotecting of the N-terminal nitrogen followed by alkylation of the N-terminal nitrogen and deprotection by known methods.
  • the coupling is accordingly done by one of the following methods:
  • a 2 , ⁇ , H ⁇ and X are as defined above followed by deprotection of the W 1 -group and coupling with the N-terminaJ amino acid, in a protected form, leading to the protected / 0534
  • the 1 H NMR and 13 C NMR measurements were performed on BRUKER AC-P 300, BRUKER 200 and BRUKER AM 500 spectrometers, the former operating at a frequency of 500.14 MHz and a 13 C freguency of 125.76 MHz and the latter at H and 13 C freguency of 300.13 MHz and 75.46 MHz respectively.
  • the samples were 10-50 mg dissolved in 0.6 ml of either of the following solvents; CDC1 3 (isotopic purity > 99.8%, Dr. Glaser AG Basel), CD 3 0D (isotopic purity > 99.95%, Dr. Glaser AG Basel) or D 2 0 (isotopic purity > 99.98%, Dr. Glaser AG Basel) .
  • the H and 13 C chemical shift values in CDC1 3 and CD 3 OD are relative to tetra ethylsilane as an external standard.
  • the H chemical shifts in D 2 0 are relative to the sodium salt of 3- (trimethylsilyl)-d 4 -propanoic acid and the 13 C chemical shifts in D 2 0 are referenced relative to 1,4-dioxane (67.3 ppm), both as external standard. Calibrating with an external standard may in some cases cause minor shift differences compared to an internal standard, however, the difference in 1 H chemical shift is less than 0.02 pp_ and in 13 C less than 0.1 ppm.
  • Thin-Layer C hromatography was carried out on commercial Merck S ilicagel 60 F 254 coated glass or aluminium plates. Visualization was by a combination of UV-light, followed by spraying with a solution prepared by mixing 372 ml of Et0H(95%), 13.8 ml of concentrated H 2 S0 4 , 4.2 ml of concentrated acetic acid and 10.2 ml of p-methoxy benzaldehyde or phosphomolybdic acid reagent (5-10 w.t % in Et0H(95%)) and heating.
  • Freeze-drying was done on a Leybold-Heraeus, model Lyovac G T 2 , apparatus.
  • Boc-(R)Cha- O H (1 eq.), HOSu (1.1 eq) and D CC or C ME- C DI ( 1.1 eq) were dissolved in acetonitrile (about 2.5 ml/mmol acid) and stirred at room temperature over night. The precipitate formed during the reaction was filtered off, the solvent evaporated and the product dried in vacuo. (When CME-CDI was used in the reaction the residue, after evaporation of the CH 3 CN, was dissolved in EtOAc and the organic phase washed with water and dried. Evaporation of the solvent gave the title compound) .
  • Boc-NH-(CH 2 ) 3 -NH 2 x HCl (prepared according to Mattingly P.G., Synthesis, 367 (1990)) (3.9 kg, 18.5 mol) in iso-propanol (24 kg) at 60-70° C was added in portions over a 30 minutes period KHC0 3 (4.2 kg, 42 mol). A slow evolution of C0 2 (g) occurs. The mixture was stirred for another 30 minutes followed by addition in portions over a 30 minutes period N-bensyloxycarbonyl-O-methyl isourea (3.74 kg, 18.0 mol). The reaction mixture was stirred at 65-70° C for 16 h, cooled to 20° C and filtered.
  • the precipitate was washed with iso-propanol (10 + 5 L) .
  • the combined filtrates was concentrated at reduced pressure keeping the heating mantle not warmer than 65-70° C.
  • EtOAc 90 L was added.
  • the reaction mixture was cooled to 20-25° C, washed with water (10 and 5 L) and brine (5 L) , and dried with Na 2 S0 4 (2 kg) .
  • After stirring the rection mixture was filtered and the filter cake was washed with EtOAc (11 and 7 L) .
  • the combined filtates were concentrated at reduced pressure keeping the heating mantle not warmer than 40-50° C.
  • Boc-(R)Cha-0H was dissolved in acetonitrile (200 mL) , N-hydroxisuccinimide (9.9 g, 81 mmol) was added. Dicyclohexylcarbodiimide (17.8 g, 81 mmol) was then added slowly and the reaction mixture was stirred overnight at room temperature. The precipitate was filtered off and the Boc- (R)Cha-OSu containing solution was evaporated. Phe-OH (48.7 g, 195 mmol), sodiumhydroxide (10.3 g, 258 mmol), water (270 mL) and finally dimethylformamide (70 mL) were added to a reaction vessel while stirring.
  • Boc-(R)Cha-OSu was dissolved in dimethylformamide (200 mL) and added slowly to the reaction vessel while maintaining the reaction temperature below 5 ⁇ C. After 3 h the solution was evaporated, the residue dissolved in water (1000 mL) and extracted with ethylacetate (2 x 300 mL) . The aqueous phase was acidified with potassium hydrogensulfate (1M) to pH 3 and extracted with ethylacetate
  • H 2 N-(R)Cha-Phe-Nag(Z) 300 mg, 0.55 mmol was dissolved in ethanol (50 mL) and trifluoroaceticacid (56 ⁇ L, 0.73 mmol) was added. The mixture was sonicated and palladium on charcoal (5%, 50 mg) was charged before it was hydrogenated at 45 psi hydrogen pressure in a Parr shaking apparatus for 19 h. The suspension was filtered through celite and after the solvent was evaporated the title compound (0.13 g, 0.31 mmol) was isolated in 56% yield.
  • H 2 N-(R)Cha-Phe-Nag(Z) 500 mg, 0.91 mmol
  • p-toluenesulphonic acid 173 mg, 0.91 mmol
  • methanol 7.5 L
  • Acetaldehyde 51 ⁇ L, 0.91 mmol
  • sodium cyanoborohydride 86 mg, 1.36 mmol
  • H 2 N-(R)Cha-Phe-Nag(Z) 500 mg, 0.91 mmol was dispersed in acetonitrile (5 mL) .
  • Methyloxalylchloride 104 ⁇ L, 1.14 mmol was added to the slurry. After 60 minutes the starting material was consumed, confirmed by HPLC, and the clear solution was evaporated.
  • the crude methylester was hydrolyzed by dissolving the residue in tetrahydrofuran (4 mL) and adding LiOH (115 mg, 2.73 mmol) dissolved in water (2 mL) . After 90 min.
  • HOOC-CO-(R)Cha-Phe-Nag(Z) (210 mg, 0.34 mmol) was dispersed in tetrahydrofuran (25 mL) and acitic acid (20 mL) was added. Palladium on charcoal (5%, 30 mg) was charged before it was hydrogenated at 45 psi hydrogen pressure in a Parr shaking apparatus for 25 h. The suspension was filtered through celite and the filter cake was washed with tetrahydrofuran and after the solvent was evaporated the crude product (257 mg) was collected. After azeotropic evaporation with three portions of toluene (tot; 50 mL) and overnight drying under vacuum the product (140 mg, 0.29 mmol) was isolated in 85% yield.
  • compositions A The compounds according to the invention can be formulated in solid dosage forms for oral administration or for topical administration to the intestines.
  • the active constituent is mixed with lactose and micro- crystalline cellulose and magnesium stearate is admixed and tablets are compressed from the mixture.
  • the active constituent is mixed with lactose and granulated with polyvinylpyrrolidone in water. After drying and milling magnesium stearate is admixed and tablets are compressed. The tablets are coated with a solution of hydroxypropylmethylcellulose, polyethyleneglycol, talc and titandioxide in water.
  • the active constituent is mixed with lactose and granulated with polyvinylpyrrolidone in water. After drying and milling microcrystalline cellulose and magnesium stearate is admixed and tablets are compressed. The tablets are coated with a solution of Eudragit L, dibutylphtalate and talc in isopropanol/aceton.
  • the active constituent is mixed with lactose and micro ⁇ crystalline cellulose and granulated with hydroxypropyl cellulose in water.
  • the granulation is extruded, spheronized and dried.
  • the granules are first coated with ethylcellulose dispersion with acetyltributylcitrate and then with Eudragit L30D dispersion with triethylcitrate and talc.
  • the granules are filled in gelatin capsules each containing 10 mg of active constituent.
  • the active constituent is mixed with lactose and micro ⁇ crystalline cellulose and granulated with hydroxypropyl cellulose in water.
  • the granulation is extruded, spheronized and dried.
  • the granules are coated with a dispersion of
  • Eudragit NE30D, Eudragit SlOO and talc in water The granules are filled in gelatin capsules each containing 100 mg of active constituent.
  • the compounds according to the invention can be formulated in pressurized aerosols or in dry powder inhalers for oral or nasal inhalation.
  • the kininogenase inhibitor is micronized to a particle size suitable for inhalation therapy (mass median diameter ⁇ 4 ⁇ m) .
  • the micronized substance is suspended in a liquid propellant mixture and filled into a container which is sealed with a metering valve.
  • the kininogenase inhibitor can be dissolved in the liquid propellant mixture with the aid of ethanol.
  • the propellants used may by chlorofluorocarbons (CFCs) or hydrofluoroalkanes (HFAs) of different formulae.
  • CFCs chlorofluorocarbons
  • HFAs hydrofluoroalkanes
  • the most frequent used CFCs are trichloromonofluoromethane (propellant 11) and dichlorodifluoromethane (propellant 12) and dichlorotetrafluoroethane (propellant 114).
  • the most frequent used HFAs are tetrafluoromethane (propellant 134a) and heptafluoropropane (propellant 227).
  • surfactant such as sorbitan trioleate, lecithin, oleic acid or other suitable substance may be used to improve the physical stability.
  • Etanol may be used as surfactant or as a medium to increase the solubility of active substance in the propellant mixture.
  • micronized kininogenase inhibitor may be used alone or mixed with a carrier substance such as lactose, mannitol or glucose.
  • a carrier substance such as lactose, mannitol or glucose.
  • Another possibility is to process the micronized powder into spheres which break up during the dosing procedure.
  • This powder or spheronized powder is filled into the drug reservoir in a singledose or multidose inhaler, e.g. the latter being Turbuhaler®.
  • a dosing unit meters the desired dose which is inhaled by the patient.
  • the kininogenase inhibitor is micronized in a jet mill to a particle size suitable for inhalation (mass diameter ⁇ 4 ⁇ m) .
  • 100 mg of the micronized powder is filled into a powder multidose inhaler (Turbuhaler®) .
  • the inhaler is equipped with a dosing unit which delivers a dose of 1 mg.
  • the kininogenase inhibitor is micronized in a jet mill to a particle size suitable for inhalation (mass diameter ⁇ 4 ⁇ m) .
  • 150 mg of the micronized powder is filled into a powder multidose inhaler (Turbuhaler®) .
  • the inhaler is equipped with a dosing unit which delivers a dose of 0.5 mg.
  • Boc tertiary butoxy carbonyl
  • LiOH Lithium hydroxide
  • NMM N-methyl morpholine
  • Ph phenyl
  • n, s, i and t have their usual meanings: normal, iso, sec and tertiary.
  • the stereochemistry for the amino acids is by default (S) if not otherwise stated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composés de la formule générale (I): A1 - A2 -NH-(CH¿2?)n - NH-C(NH)-NH2, dans laquelle n représente un entier compris entre 2 et 6 inclus; de préférence 3 ou 4; A?1¿ représente un fragment de structure répondant aux formules (IIa), (IIb), (IIc), (IId) ou (IIe); et A2 représente le fragment de la structure (a). Des procédés de préparation de ces composés, leur utilisation et des formulations pharmaceutiques les contenant sont également décrits.
PCT/SE1994/000534 1993-06-03 1994-06-02 Nouveaux derives peptidiques WO1994029335A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7501664A JPH08511017A (ja) 1993-06-03 1994-06-02 新規なペプチド誘導体
EP94917871A EP0701567A1 (fr) 1993-06-03 1994-06-02 Nouveaux derives peptidiques
AU69408/94A AU685465B2 (en) 1993-06-03 1994-06-02 New peptides derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939301911A SE9301911D0 (sv) 1993-06-03 1993-06-03 New peptide derivatives
SE9301911-5 1993-06-03

Publications (1)

Publication Number Publication Date
WO1994029335A1 true WO1994029335A1 (fr) 1994-12-22

Family

ID=20390161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1994/000534 WO1994029335A1 (fr) 1993-06-03 1994-06-02 Nouveaux derives peptidiques

Country Status (5)

Country Link
EP (1) EP0701567A1 (fr)
JP (1) JPH08511017A (fr)
AU (1) AU685465B2 (fr)
SE (1) SE9301911D0 (fr)
WO (1) WO1994029335A1 (fr)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578574A (en) * 1994-03-04 1996-11-26 Eli Lilly And Company Antithrombotic agents
US5599793A (en) * 1994-03-04 1997-02-04 Eli Lilly And Company Antithromobotic agents
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
EP0841933A4 (fr) * 1995-07-25 1998-08-05 Univ Pennsylvania Compositions d'inhibiteur de bowman-birk destinees au traitement de maladies inflammatoires
US5885967A (en) * 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6258597B1 (en) 1997-09-29 2001-07-10 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6300314B1 (en) 1998-05-04 2001-10-09 Point Therapeutics, Inc. Hematopoietic stimulation
US6355614B1 (en) 1998-06-05 2002-03-12 Point Therapeutics Cyclic boroproline compounds
US6692753B2 (en) 1997-05-07 2004-02-17 Trustees Of Tufts College Potentiation of the immune response
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
RU2301225C2 (ru) * 2002-03-08 2007-06-20 Ферринг Бв Селективные дипептидные ингибиторы калликреина, фармацевтическая композиция на их основе, их применение и способ лечения
US7265118B2 (en) 1998-08-21 2007-09-04 Point Therapeutics, Inc. Regulation of substrate activity
US7879863B2 (en) 2004-03-31 2011-02-01 Ajinomoto Co., Inc. Aniline derivatives
WO2011051671A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminopyridine comme inhibiteurs de la kallicréine
WO2011051673A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminothiazole utiles comme inhibiteurs de la klk1
WO2011051672A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés azaindole
WO2013005045A1 (fr) 2011-07-07 2013-01-10 Kalvista Pharmaceuticals Limited Dérivés de benzylamine en tant qu'inhibiteurs de kallikréine du plasma
WO2014006414A1 (fr) 2012-07-06 2014-01-09 Kalvista Pharmaceuticals Limited Polymorphes d'hydrochlorure de n-[(r)-1-[(s)-1-(4-aminométhyl-benzylcarbamoyl)-2-phényl-éthylcarbamoyl]-2-(4-éthoxy-phényl)-éthyl]-benzamide
WO2014108685A1 (fr) * 2013-01-09 2014-07-17 Kalvista Pharmaceuticals Limited Compositions pharmaceutiques
WO2016083816A1 (fr) 2014-11-27 2016-06-02 Kalvista Pharmaceuticals Limited Dérivés de n-((hétéroarylméthyl)-hétéroaryl-carboxamide utilisés en tant qu'inhibiteurs de la kallikréine plasmatique
US9533987B2 (en) 2013-05-23 2017-01-03 Kalvista Pharmaceuticals Limited Heterocyclic derivates
US9670157B2 (en) 2013-01-08 2017-06-06 Kalvista Pharmaceuticals Limited Benzylamine derivatives
US9738641B2 (en) 2013-08-14 2017-08-22 Kalvista Pharmaceuticals Limited Bicyclic inhibitors
US9834513B2 (en) 2013-01-08 2017-12-05 Kalvista Pharmceuticals Limited Benzylamine derivatives
US10221161B2 (en) 2013-08-14 2019-03-05 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US10364238B2 (en) 2014-11-27 2019-07-30 Kalvista Pharmaceuticals Limited N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
US10752607B2 (en) 2016-06-01 2020-08-25 Kalvista Pharmaceuticals Limited Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors
US10781181B2 (en) 2014-11-27 2020-09-22 Kalvista Pharmaceuticals Limited N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
WO2020249977A1 (fr) 2019-06-14 2020-12-17 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2020249979A1 (fr) 2019-06-14 2020-12-17 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
EP3760622A1 (fr) 2016-05-31 2021-01-06 Kalvista Pharmaceuticals Limited Dérivé de pyrazole comme inhibiteurs de la kallikréine plasmatique
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
WO2021116679A1 (fr) 2019-12-09 2021-06-17 Kalvista Pharmaceuticals Limited Traitements d'un oedème maculaire diabétique et d'une acuité visuelle altérée
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
US11230537B2 (en) 2016-06-01 2022-01-25 Kalvista Pharmaceuticals Limited Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
US11234939B2 (en) 2017-11-29 2022-02-01 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
US11242333B2 (en) 2013-08-14 2022-02-08 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
WO2022079446A1 (fr) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Traitements de l'œdème de quincke
WO2022084693A1 (fr) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
WO2022172006A1 (fr) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2023002219A1 (fr) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US11584735B2 (en) 2017-11-29 2023-02-21 Kalvista Pharmaceuticals Limited Solid forms of a plasma kallikrein inhibitor and salts thereof
WO2023209381A1 (fr) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations d'un inhibiteur de la kallicréine plasmatique
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
WO2024180100A1 (fr) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited Nouvelle forme solide d'un inhibiteur de la kallicréine plasmatique
US12110288B2 (en) 2019-12-04 2024-10-08 Omeros Corporation MASP-2 inhibitors and methods of use
US12195427B2 (en) 2018-05-29 2025-01-14 Omeros Corporation MASP-2 inhibitors and methods of use
WO2025172692A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire
WO2025172693A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2085444A (en) * 1979-06-12 1982-04-28 Richter Gedeon Vegyeszet Novel Anticoagulant agmatine derivatives and process for the preparation thereof
WO1992004371A1 (fr) * 1990-09-07 1992-03-19 Ferring Peptide Research Partnership Kb Inhibiteurs de la kininogenase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2085444A (en) * 1979-06-12 1982-04-28 Richter Gedeon Vegyeszet Novel Anticoagulant agmatine derivatives and process for the preparation thereof
WO1992004371A1 (fr) * 1990-09-07 1992-03-19 Ferring Peptide Research Partnership Kb Inhibiteurs de la kininogenase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brazilian J. Med. Biol. Res., Volume 20, 1987, L.A.F. FERREIRA et al., "Kallikrein Isolated from Commersial Crystalline Pepsin Preparations", page 511 - page 520. *

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230074B2 (en) 1991-10-22 2007-06-12 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
US6124277A (en) * 1994-03-04 2000-09-26 Eli Lilly And Company Antithrombotic agents
US5599793A (en) * 1994-03-04 1997-02-04 Eli Lilly And Company Antithromobotic agents
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5885967A (en) * 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5578574A (en) * 1994-03-04 1996-11-26 Eli Lilly And Company Antithrombotic agents
US6090787A (en) * 1994-03-04 2000-07-18 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
EP0841933A4 (fr) * 1995-07-25 1998-08-05 Univ Pennsylvania Compositions d'inhibiteur de bowman-birk destinees au traitement de maladies inflammatoires
US6875737B1 (en) 1996-06-28 2005-04-05 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6503882B2 (en) 1997-05-07 2003-01-07 Trustees Of Tufts College Treatment of HIV
US6692753B2 (en) 1997-05-07 2004-02-17 Trustees Of Tufts College Potentiation of the immune response
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6258597B1 (en) 1997-09-29 2001-07-10 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6703238B2 (en) 1997-09-29 2004-03-09 Point Therapeutics, Inc. Methods for expanding antigen-specific T cells
US7276371B2 (en) 1997-09-29 2007-10-02 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6770628B2 (en) 1998-05-04 2004-08-03 Point Therapeutics, Inc. Hematopoietic stimulation
US6300314B1 (en) 1998-05-04 2001-10-09 Point Therapeutics, Inc. Hematopoietic stimulation
US7067489B2 (en) 1998-05-04 2006-06-27 Point Therapeutics, Inc. Hematopoietic stimulation
US6355614B1 (en) 1998-06-05 2002-03-12 Point Therapeutics Cyclic boroproline compounds
US7265118B2 (en) 1998-08-21 2007-09-04 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US7259138B2 (en) 1999-05-25 2007-08-21 Point Therapeutics, Inc. Anti-tumor agents
US6949514B2 (en) 1999-05-25 2005-09-27 Point Therapeutics, Inc. Anti-tumor agents
US7282484B2 (en) 1999-05-25 2007-10-16 Point Therapeutics, Inc. Anti-tumor agents
RU2301225C2 (ru) * 2002-03-08 2007-06-20 Ферринг Бв Селективные дипептидные ингибиторы калликреина, фармацевтическая композиция на их основе, их применение и способ лечения
KR100974633B1 (ko) * 2002-03-08 2010-08-06 밴티아 리미티드 칼리크레인의 선택적 디펩타이드 억제제
US7879863B2 (en) 2004-03-31 2011-02-01 Ajinomoto Co., Inc. Aniline derivatives
WO2011051672A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés azaindole
WO2011051673A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminothiazole utiles comme inhibiteurs de la klk1
WO2011051671A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminopyridine comme inhibiteurs de la kallicréine
WO2013005045A1 (fr) 2011-07-07 2013-01-10 Kalvista Pharmaceuticals Limited Dérivés de benzylamine en tant qu'inhibiteurs de kallikréine du plasma
US9051249B2 (en) 2011-07-07 2015-06-09 Kalvista Pharmaceuticals Limited Benzylamine derivatives as inhibitors of plasma kallikrein
US9234000B2 (en) 2011-07-07 2016-01-12 Kalvista Pharmaceuticals Limited Benzylamine derivatives as inhibitors of plasma kallikrein
WO2014006414A1 (fr) 2012-07-06 2014-01-09 Kalvista Pharmaceuticals Limited Polymorphes d'hydrochlorure de n-[(r)-1-[(s)-1-(4-aminométhyl-benzylcarbamoyl)-2-phényl-éthylcarbamoyl]-2-(4-éthoxy-phényl)-éthyl]-benzamide
US9512065B2 (en) 2012-07-06 2016-12-06 Kalvista Pharmaceuticals Limited Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride
US9834513B2 (en) 2013-01-08 2017-12-05 Kalvista Pharmceuticals Limited Benzylamine derivatives
US9670157B2 (en) 2013-01-08 2017-06-06 Kalvista Pharmaceuticals Limited Benzylamine derivatives
WO2014108685A1 (fr) * 2013-01-09 2014-07-17 Kalvista Pharmaceuticals Limited Compositions pharmaceutiques
US10478409B2 (en) 2013-01-09 2019-11-19 Kalvista Pharmaceuticals Limited Pharmaceutical compositions
US9849100B2 (en) 2013-01-09 2017-12-26 Kalvista Pharmaceuticals Limited Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities
US9533987B2 (en) 2013-05-23 2017-01-03 Kalvista Pharmaceuticals Limited Heterocyclic derivates
EP3305778A1 (fr) 2013-05-23 2018-04-11 Kalvista Pharmaceuticals Limited Inhibiteurs de kallicreine plasmique
US11242333B2 (en) 2013-08-14 2022-02-08 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US10221161B2 (en) 2013-08-14 2019-03-05 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US9738641B2 (en) 2013-08-14 2017-08-22 Kalvista Pharmaceuticals Limited Bicyclic inhibitors
US11001578B2 (en) 2014-11-27 2021-05-11 Kalvista Pharmaceuticals Limited N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
US10364238B2 (en) 2014-11-27 2019-07-30 Kalvista Pharmaceuticals Limited N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
WO2016083816A1 (fr) 2014-11-27 2016-06-02 Kalvista Pharmaceuticals Limited Dérivés de n-((hétéroarylméthyl)-hétéroaryl-carboxamide utilisés en tant qu'inhibiteurs de la kallikréine plasmatique
US10611758B2 (en) 2014-11-27 2020-04-07 Kalvista Pharmaceuticals Limited N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
EP3567037A1 (fr) 2014-11-27 2019-11-13 Kalvista Pharmaceuticals Limited Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
US10781181B2 (en) 2014-11-27 2020-09-22 Kalvista Pharmaceuticals Limited N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
US11084809B2 (en) 2014-11-27 2021-08-10 Kalvista Pharmaceuticals Limited N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
EP4039681A1 (fr) 2014-11-27 2022-08-10 Kalvista Pharmaceuticals Limited Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
EP3556752A1 (fr) 2014-11-27 2019-10-23 Kalvista Pharmaceuticals Limited Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
US11198691B2 (en) 2014-11-27 2021-12-14 Kalvista Pharmaceuticals Limited N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
US11180484B2 (en) 2016-05-31 2021-11-23 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
EP3760622A1 (fr) 2016-05-31 2021-01-06 Kalvista Pharmaceuticals Limited Dérivé de pyrazole comme inhibiteurs de la kallikréine plasmatique
US10752607B2 (en) 2016-06-01 2020-08-25 Kalvista Pharmaceuticals Limited Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors
EP4151630A1 (fr) 2016-06-01 2023-03-22 Kalvista Pharmaceuticals Limited Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein
US11230537B2 (en) 2016-06-01 2022-01-25 Kalvista Pharmaceuticals Limited Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
US11739068B2 (en) 2016-06-01 2023-08-29 Kalvista Pharmaceuticals Limited Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof
US11234939B2 (en) 2017-11-29 2022-02-01 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
US11584735B2 (en) 2017-11-29 2023-02-21 Kalvista Pharmaceuticals Limited Solid forms of a plasma kallikrein inhibitor and salts thereof
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US12195427B2 (en) 2018-05-29 2025-01-14 Omeros Corporation MASP-2 inhibitors and methods of use
EP4282474A2 (fr) 2019-06-14 2023-11-29 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2020249977A1 (fr) 2019-06-14 2020-12-17 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2020249979A1 (fr) 2019-06-14 2020-12-17 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
WO2021028649A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
US11613527B2 (en) 2019-08-09 2023-03-28 Kalvista Pharmaceuticals Limited Enzyme inhibitors
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
US12110288B2 (en) 2019-12-04 2024-10-08 Omeros Corporation MASP-2 inhibitors and methods of use
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
WO2021116679A1 (fr) 2019-12-09 2021-06-17 Kalvista Pharmaceuticals Limited Traitements d'un oedème maculaire diabétique et d'une acuité visuelle altérée
WO2022079446A1 (fr) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Traitements de l'œdème de quincke
WO2022084693A1 (fr) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
WO2022172006A1 (fr) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2023002219A1 (fr) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2023209381A1 (fr) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations d'un inhibiteur de la kallicréine plasmatique
EP4480545A2 (fr) 2022-04-27 2024-12-25 Kalvista Pharmaceuticals Limited Formulations d'un inhibiteur de la kallicréine plasmatique
WO2024180100A1 (fr) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited Nouvelle forme solide d'un inhibiteur de la kallicréine plasmatique
WO2025172692A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire
WO2025172693A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire

Also Published As

Publication number Publication date
JPH08511017A (ja) 1996-11-19
AU685465B2 (en) 1998-01-22
AU6940894A (en) 1995-01-03
SE9301911D0 (sv) 1993-06-03
EP0701567A1 (fr) 1996-03-20

Similar Documents

Publication Publication Date Title
AU685465B2 (en) New peptides derivatives
US4189604A (en) Bestatin
EP0479489B1 (fr) Agents antithrombotiques à base de tripeptides
AU772024B2 (en) Inhibitors of urokinase and blood vessel formation
IE60128B1 (en) Hydroxylamine derivatives,their preparation and use as medicaments
US6683055B1 (en) Low molecular weight inhibitors of complement proteases
US6831196B2 (en) Urokinase inhibitors
CA2082748A1 (fr) Agents antithrombotiques
HK18696A (en) Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same
JPH05504775A (ja) トロンビンの阻害剤および基質
EP0124317A2 (fr) Dérivés de la proline
JPS61189298A (ja) 新規オリゴペプチジルアルギニノール誘導体
JPS62126158A (ja) アミノカルボニルレニン抑制剤
CA2170896A1 (fr) Kininogenases, agents inhibiteurs
BG60739B2 (bg) Трипептиди,влияещи върху централната нервна система и метод за тяхното получаване
US4240975A (en) Bestatin
CA2224721A1 (fr) Inhibiteurs de la calpaine destines au traitement de maladies neurodegeneratives
CA2370267A1 (fr) Promedicaments d'inhibiteurs de la thrombine
JP2005526762A (ja) ウロキナーゼの阻害剤、それらの製造および使用
US20050119190A1 (en) Inhibitors of the blood-clotting factor xa, production thereof and use of the same
US5922697A (en) Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
AU721261B2 (en) Peptide inhibitors of hematopoietic cell proliferation
CA2329929A1 (fr) Amidinohydrazones d'acide amine, alcoxyguanidines et aminoguanidines utilises comme inhibiteurs de l'enzyme protease
CA2163011A1 (fr) Nouveaux derives de peptides
JPH0532602A (ja) ナフチルメチルアミン誘導体及びこれを含有するレニン阻害剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 1995 302733

Country of ref document: US

Date of ref document: 19950221

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994917871

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2163011

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994917871

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1994917871

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994917871

Country of ref document: EP